Related Experiment Videos
Therapeutic apheresis for renal disorders
1Division of Nephrology, University of Connecticut Health Center, Farmington 06030, USA. kaplan@nso.uchc.edu
Summary
Therapeutic plasma exchange effectively removes harmful immunoglobulins and antibodies, offering a valuable treatment for autoimmune kidney diseases and related conditions like thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Area of Science:
- Nephrology
- Immunology
- Hematology
Background:
- Primary renal diseases often involve antibody deposition or autoimmune processes.
- Nephrotoxic immunoglobulins, such as myeloma light chains and cryoglobulins, can cause kidney damage.
- Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are related microangiopathic hemolytic anemias affecting the kidneys.
Purpose of the Study:
- To review the renal indications for therapeutic plasma exchange (TPE).
- To highlight TPE's role in managing autoimmune-related kidney diseases.
- To discuss TPE's utility in treating TTP and HUS.
Main Methods:
- Review of existing literature on therapeutic plasma exchange in renal diseases.
- Analysis of studies investigating TPE for antibody-mediated glomerulonephritis and vasculitis.
- Examination of TPE efficacy in thrombotic microangiopathies.
Main Results:
- Therapeutic plasma exchange rapidly removes pathogenic immunoglobulins.
- TPE is an established treatment for various autoimmune renal diseases.
- TPE has demonstrated significant benefit in managing TTP and HUS.
Conclusions:
- Therapeutic plasma exchange is a key therapeutic option for specific autoimmune renal conditions.
- TPE plays a crucial role in the management of antibody-mediated kidney diseases.
- The utility of TPE extends to related thrombotic microangiopathies, improving patient outcomes.